How to Value a De Novo Veterinary Practice Startup

The veterinary M&A market changed dramatically over the last decade. Mars Petcare (via VCA and Banfield), National Veterinary Associates, Thrive Pet Healthcare, and a dozen PE-backed consolidators have been paying eye-watering multiples — 15-20x EBITDA in some cases — for stabilized general practices. I've watched vets with a single hospital walk away with $4M+ exits that would have been impossible in 2015.

That's the headline. The reality for a de novo veterinary practice — a hospital that opened in the last three years — is entirely different. None of those consolidators will return your call. Here's what actually happens when you try to value or sell a startup vet practice.

The De Novo Vet Ramp-Up Curve

A scratch-start general veterinary hospital follows a reasonably predictable ramp, assuming a workable location and a capable owner. Year 1 revenue of $400K-$650K, Year 2 of $800K-$1.1M, Year 3 of $1.2M-$1.6M, and stabilization in Year 4-5 around $1.6M-$2.2M for a single-doctor hospital. Two-doctor hospitals can push $2.5M-$3.5M at maturity.

The ramp is slower than dental for a few reasons. Pet owners are less insurance-driven, so your marketing has to build a direct relationship. Wellness plans take 18-24 months to mature into a meaningful recurring revenue stream. And veterinary practices depend heavily on word-of-mouth, which compounds slowly but eventually becomes the dominant growth channel.

EBITDA during the ramp is usually negative through month 12-18 and breakeven through month 24-30. Stabilized hospitals run 15-22% EBITDA margins, so a $1.8M hospital might produce $300K-$400K in EBITDA. Your de novo almost certainly doesn't have that yet.

Why Corporate Buyers Will Not Engage

The veterinary consolidators have been very disciplined about what they will and won't buy. Their underwriting model is built around stabilized EBITDA, and the minimum bar is usually $500K-$750K in trailing EBITDA, which implies roughly $2.5M-$4M in revenue. They need trailing twelve months of clean financials with a trend line that supports the multiple.

A de novo at $900K in Year 2 with $50K in EBITDA gives them nothing to underwrite. They can't pay 15x on $50K — that's a $750K check for a hospital that still has execution risk baked into every month. And they can't pay 15x on projected stabilized EBITDA because their investment committees will not approve it. So they politely decline and say "come back in two years."

I've seen exactly two scenarios where a consolidator will engage with a startup. First, if your hospital sits inside an existing referral catchment of one of their hub hospitals and they want the geographic coverage. Second, if you already own and operate a mature hospital and your de novo is the second location of a mini-platform they can acquire together. Neither applies to most solo de novos.

The Realistic Buyer Pool for Startup Vet Practices

When a consolidator says no, these are the buyers who actually show up.

Associate veterinarians looking to own. The classic private buyer. Another vet — often someone who has been an associate for 5-10 years — wants their own hospital and would rather buy a going concern than build from scratch. They pay based on what the hospital can afford to pay them as an owner-operator. For a de novo, that usually translates to 0.8-1.3x trailing revenue or 2-3x SDE, heavily discounted from the stabilized multiples in my industry multiples guide.

Local multi-hospital owners. Veterinarians who already own 2-5 hospitals and want to add another. These buyers understand ramp-ups firsthand, which is both good and bad. Good because they'll engage when a consolidator won't. Bad because they've seen every trick and won't pay a premium for projected performance.

Asset-only buyers. For de novos that are struggling — say, Year 2 revenue under $500K with no clear trajectory — the most likely buyer pays for the buildout, equipment, and lease at 40-55% of original cost, period. No goodwill, no going-concern premium. This is the outcome nobody wants but many end up with.

How Valuation Actually Gets Calculated

For a de novo with positive trajectory, buyers typically use one of two methods.

The first is discounted stabilization. The buyer projects your stabilized Year 5 EBITDA, applies a modest multiple (say, 4-6x rather than the 12-15x a stabilized hospital would command), then discounts heavily for the risk that you don't actually get there. A projected $350K stabilized EBITDA might support a $700K-$1.1M offer today — significantly less than the $4M+ the same hospital would command once it stabilizes.

The second is revenue run-rate with a haircut. The buyer takes your most recent 3-6 months of revenue, annualizes it, and pays 0.8-1.2x. A hospital running at $1.1M annualized might get a $950K-$1.3M offer. This is cleaner math but ignores the trajectory, which usually benefits the seller rather than the buyer.

Whichever method the buyer uses, the answer almost always lands in the same range: somewhere between your invested capital and a small premium above it. De novo exits rarely produce the kind of wealth-creation event you read about in the veterinary trade press.

What Actually Drives Value on a Startup Sale

If you're planning to sell a de novo in the next 12 months, focus on the things that de-risk the deal from a buyer's perspective.

Active client count and visit frequency. Buyers care less about your top-line revenue than about how many unique pets have visited in the last 12 months and how often they return. A hospital with 1,200 active patients and a 65% annual return rate is a different asset than one with 800 patients and a 35% return rate, even at the same revenue. Pull the numbers from your practice management software before you go to market.

Wellness plan penetration. Hospitals with 15%+ of active clients on a wellness plan have a built-in recurring revenue base that survives an ownership transition. This is one of the few things that genuinely moves the number on a de novo.

Staff retention. A credentialed veterinary technician who has been with you since month one is a massive asset. Veterinary staffing shortages have made every buyer paranoid about post-close attrition. Get your key staff bought in — including, if appropriate, small retention bonuses — before you list.

A lease that actually works. Most de novo vet practices signed 10-year leases at the time of buildout, which is good. Make sure the assignment clause doesn't require landlord consent that can't be unreasonably withheld, and make sure any personal guarantee releases on assignment.

The Honest Math

Every de novo vet I've worked with who tried to sell in Year 2 regretted it. The consolidator multiples are real, but they only apply after stabilization. Selling during the ramp means capturing none of that upside while still eating all the downside of the startup phase.

If your situation forces a sale, price realistically — expect to recover your invested capital plus a small premium, not a headline-grabbing multiple. If your situation lets you wait, push through to Year 4-5. The difference between a $1.1M de novo exit and a $4.5M stabilized exit is often just 24-36 more months of patience.